<DOC>
	<DOCNO>NCT00576199</DOCNO>
	<brief_summary>This single-arm , open-label study assess efficacy safety Avastin ( bevacizumab ) treatment combine transarterial chemoembolisation ( TACE ) patient localize unresectable liver cancer . Patients treat TACE 8 10 week interval 4 session ( continuation depend investigator 's discretion ) . Avastin 5 mg/kg intravenously administer 24-48 hour prior TACE session every 2 week TACE session disease progression .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Transarterial Chemoembolisation ( TACE ) Treatment Patients With Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , â‰¥ 18 year age . Liver cancer , suitable resection . At least 1 measurable lesion , overall tumor lesion occupy &lt; 50 % liver volume Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Patients receive concurrent radiotherapy immunotherapy . Patients receive previous chemotherapy , biological agent , radiotherapy . Prior transarterial chemoembolisation ( TACE ) transarterial embolisation ( TAE ) . Prior liver transplantation liver resection . Current recent ( within 10 day study start ) use fulldose anticoagulant therapeutic purpose . Patients high risk esophageal/gastric varix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>